Market Newsdesk

March 22, 2023 4:58 pm

BlackRock® Canada Announces Final March Cash Distributions for the iShares® Premium Money Market ETF

TORONTO, March 22, 2023 (GLOBE NEWSWIRE) — BlackRock Asset Management Canada Limited (“BlackRock Canada”), an indirect, wholly-owned subsidiary of BlackRock, Inc. (NYSE: BLK), today announced the final March 2023 cash distributions for the iShares Premium Money Market ETF. Unitholders of record on March 23, 2023 will receive cash distributions payable on March 31, 2023.

Details regarding the final “per unit” distribution amounts are as follows:

Fund Name	Fund Ticker	Cash Distribution Per Unit ($)
iShares Premium Money Market ETF	CMR	0.171

Further information on the iShares ETFs can be found at http://www.blackrock.com/ca.

About BlackRock

BlackRock’s purpose is to help more and more people experience financial well-being. As a fiduciary to investors and a leading provider of financial technology, we help millions of people build savings that serve them throughout their lives by making investing easier and more affordable. For additional information on BlackRock, please visit www.blackrock.com/corporate | Twitter: @BlackRockCA

About iShares

iShares unlocks opportunity across markets to meet the evolving needs of investors. With more than twenty years of experience, a global line-up of 1300+ exchange traded funds (ETFs) and US$2.91 trillion in assets under management as of December 31, 2022, iShares continues to drive progress for the financial industry. iShares funds are powered by the expert portfolio and risk management of BlackRock.

iShares^® ETFs are managed by BlackRock Asset Management Canada Limited.

Commissions, trailing commissions, management fees and expenses all may be associated with investing in iShares ETFs. Please read the relevant prospectus before investing. The funds are not guaranteed, their values change frequently and past performance may not be repeated. Tax, investment and all other decisions should be made, as appropriate, only with guidance from a qualified professional.

Contact for Media:

Reem Jazar
Email: [email protected]

March 22, 2023 4:55 pm

Webster Raises Prime Lending Rate to 8.00 Percent

Webster Raises Prime Lending Rate to 8.00 Percent

STAMFORD, Conn.–(BUSINESS WIRE)–
Webster Financial Corporation (NYSE: WBS), the holding company for Webster Bank, N.A. and its HSA Bank division, announced today that it has raised its prime lending rate to 8.00 percent from 7.75 percent, effective March 23, 2023.

About Webster

Webster Financial Corporation (NYSE:WBS) is the holding company for Webster Bank, National Association and its HSA Bank Division. Webster is a leading commercial bank in the Northeast that provides a wide range of digital and traditional financial solutions across three differentiated lines of business: Commercial Banking, Consumer Banking and its HSA Bank division, one of the country’s largest providers of employee benefits solutions. Headquartered in Stamford, CT, Webster is a values-driven organization with over $70 billion in assets. Its core footprint spans the northeastern U.S. from New York to Massachusetts, with certain businesses operating in extended geographies. Webster Bank is a member of the FDIC and an equal housing lender. For more information about Webster, including past press releases and the latest annual report, visit the Webster website at www.websterbank.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230322005752/en/

Media Contact:

Alice Ferreira, 203-578-2610

[email protected]

Investor Contact:

Emlen Harmon, 212-309-7646

[email protected]

KEYWORDS: Connecticut United States North America

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

March 22, 2023 4:53 pm

SQZ Biotechnologies Announces Confirmed Complete Response in HPV16+ Solid Tumor Patient in the Lowest-Dose Cohort of the SQZ-AAC-HPV-101 Clinical Trial

SQZ Biotechnologies Announces Confirmed Complete Response in HPV16+ Solid Tumor Patient in the Lowest-Dose Cohort of the SQZ-AAC-HPV-101 Clinical Trial

A confirmed complete response was observed in the first patient in the lowest-dose cohort of the Phase 1 SQZ-AAC-HPV-101 clinical trial
Following review and recommendation by the Study Safety Committee, the Company is advancing SQZ-AAC-HPV-101 trial to the highest-dose cohort
Strong enrollment rates; Anticipate initial clinical data from the highest-dose cohort in the fourth quarter of 2023

WATERTOWN, Mass.–(BUSINESS WIRE)–
SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies, today announced that, according to RECIST 1.1 criteria, a confirmed complete response was observed in the first patient in the lowest-dose cohort of the Phase 1 SQZ-AAC-HPV-101 clinical trial. The company has decided to continue to enroll patients in the SQZ-AAC-HPV-101 clinical trial. The second and third patients have also been enrolled in the trial. The company has completed the dose-limiting toxicity period for the lowest-dose cohort. The Study Safety Committee has completed their review and recommends that the company enroll patients in the highest-dose cohort. The company anticipates initial clinical data from the highest-dose cohort by the fourth quarter of 2023.

“Although early in this trial, we have observed good tolerability among the patients. The confirmed complete response observed in this patient demonstrates the potential of the investigational therapy’s intended immunotherapy mechanism,” said Richard T. Maziarz, M.D., Professor of Medicine and Investigator, Oregon Health & Science University.

“We are motivated by the clinical response in our first patient in the AAC trial,” said Marshelle Smith Warren, M.D., Chief Medical Officer at SQZ Biotechnologies. “We find it encouraging that the confirmed complete response occurred in our lowest-dose cohort. It is still early days, but we are optimistic as we look to enroll additional patients and anticipate initial data from the highest-dose cohort in the fourth quarter of this year.”

Patient Characteristics & Treatment Journey

The patient is a 61-year-old male with a history of metastatic HPV16+ rectal squamous cell carcinoma. The patient had two prior lines of treatment but had not been treated with immune checkpoint inhibitors. The patient remains on study and the treatment has been well tolerated to date.

In December 2022, after two cycles of SQZ-AAC-HPV, a CT scan showed reduction of the target lesion to meet RECIST 1.1 criteria for a partial response. In February 2023, after four cycles of SQZ-AAC-HPV, a CT scan showed further reduction of the target lesion which was consistent with a confirmed partial response by RECIST 1.1 criteria. In March 2023, after seven cycles of SQZ-AAC-HPV, a CT scan confirmed the complete response by RECIST 1.1 criteria.

An investor presentation is available on the Events & Presentations page within the investor relations section of the company’s corporate website, investors.sqzbiotech.com. Based on guidance from the SEC, investors should note that the company may utilize its corporate website to post updated corporate and scientific presentations. It is possible that the information posted there could be deemed to be material information.

About SQZ-AAC-HPV

SQZ® Activating Antigen Carriers (AAC) are derived from red blood cells (RBCs) engineered with the Cell Squeeze® technology to contain tumor-specific antigens and adjuvant. Cell Squeeze® is designed to increase the phosphatidylserine (PS) on the surface of the AACs resulting in the AACs resembling aged RBCs. AACs are designed to take advantage of the natural physiological process of aged RBC clearance by resident, professional APCs in lymphoid organs. These professional APCs can subsequently prime endogenous T cells to potentially drive antitumor activity. The company has an ongoing Phase 1 clinical trial for the SQZ-AAC-HPV investigational therapy in HPV16+ advanced or metastatic tumors.

ENVOY-001 Trial Design

SQZ-AAC-HPV is being evaluated in a Phase 1 clinical trial (ENVOY-001. SQZ-AAC-HPV-101) for the treatment of HPV16+ advanced or metastatic solid tumors. The investigational candidate, which targets E6 and E7 oncoproteins, is being studied as a monotherapy and in combination with immune checkpoint inhibitors. The study consists of two parts. The first part is designed to assess the safety and tolerability of multiple doses of SQZ-AAC-HPV monotherapy in treatment-experienced patients. The second part of the study will assess safety and tolerability of SQZ-AAC-HPV in combination with nivolumab and/or ipilimumab.

About Human Papillomavirus Positive Cancers

Human papillomavirus (HPV) is one of the most common viruses worldwide and certain strains persist for many years, often leading to cancer. According to the Centers for Disease Control (CDC), in the United States HPV+ tumors represent 3% of all cancers in women and 2% of all cancers in men, resulting in over 39,000 new cases of HPV+ tumors every year. HPV infection is larger outside of the U.S., and according to the International Journal of Cancer, HPV+ tumors account for 4.5% of all cancers worldwide resulting in approximately 630,000 new cases every year. According to the CDC, HPV infection plays a significant role in the formation of more than 90% of anal and cervical cancers, and most cases of vaginal (75%), oropharyngeal (70%), vulval (70%) and penile (60%) cancers.

About SQZ Biotechnologies

SQZ Biotechnologies is a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies. The company’s proprietary Cell Squeeze® technology offers the unique ability to deliver multiple biological materials into many patient cell types to engineer what the company believes can be a broad range of potential therapeutics. The company’s goal is to create well-tolerated cell therapies that can provide therapeutic benefit for patients and improve the patient experience over existing cell therapy approaches. With production timelines under 24 hours and the opportunity to eliminate preconditioning and lengthy hospital stays, the company believes its approach could change the way people think about cell therapies. For more information, please visit www.sqzbiotech.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements relating to the timing and outcome of the company’s clinical trials, clinical safety and efficacy of its therapeutic candidates and the potential addressable market for the company’s therapeutic candidates. These forward-looking statements are based on management’s current expectations. Actual results could differ from those projected in any forward-looking statements due to several risk factors. Such factors include, among others, risks and uncertainties related to the company’s significant losses incurred since inception and expectation to incur significant additional losses for the foreseeable future; the company’s need for additional funding; the development of the company’s initial product candidates, upon which its business is highly dependent; the impact of the COVID-19 pandemic on the company’s operations and clinical activities; the lengthy, expensive, and uncertain process of clinical drug development, including uncertain outcomes of clinical trials and potential delays in regulatory approval; and protection of the company’s proprietary technology, intellectual property portfolio and the confidentiality of its trade secrets. These and other important factors discussed under the caption “Risk Factors” in the company’s Quarterly Report on Form 10-Q, the company’s Annual Report on Form 10-K, and other filings with the U.S. Securities and Exchange Commission could cause actual results to differ materially from those indicated by the forward-looking statements. Any forward-looking statements represent management’s estimates as of this date and the company undertakes no duty to update these forward-looking statements, whether as a result of new information, the occurrence of current events, or otherwise, unless required by law.

Certain information contained in this press release relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the company’s own internal estimates and research. While the company believes these third-party sources to be reliable as of the date of this press release, the company has not independently verified, and the company makes no representation as to the adequacy, fairness, accuracy, or completeness of any information obtained from third-party sources.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230322005191/en/

SQZ Biotechnologies Investor and Media Relations:

Mike Kaiser

[email protected]

857-760-0398

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Oncology Health Infectious Diseases Clinical Trials Pharmaceutical Biotechnology

MEDIA:

Logo

March 22, 2023 4:48 pm

SQZ Biotechnologies Reports Full Year 2022 Financial Results and Recent Portfolio Updates

SQZ Biotechnologies Reports Full Year 2022 Financial Results and Recent Portfolio Updates

Strategically Focused Company Structure to Prioritize Clinical Development and Deliver Critical, Clinical-Stage Data
SQZ^® eAPC Phase 1/2 Trial Enrollment on Track; Anticipate Data for the Highest-Dose Monotherapy Cohort in Mid-2023
Phase 1 SQZ-AAC-HPV-101 Clinical Trial to Continue Following the Recent Observation of a Confirmed Complete Response in the First Patient in the Lowest-Dose Cohort; Anticipate Data for the Highest-Dose Cohort in the Fourth Quarter of 2023

WATERTOWN, Mass.–(BUSINESS WIRE)–
SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies, today reported full year 2022 financial results and recent portfolio updates.

“The team is focused on our key initiatives of advancing our SQZ^® eAPC and SQZ^® AAC programs,” said Howard Bernstein, M.D., Ph.D., Interim Chief Executive Officer and Member of the Board of Directors. “After the restructuring in December, we made important changes to align our talent to fully support our clinical development efforts—we are now primed to deliver on multiple clinical milestones over the next 12 months. We are encouraged by the observation of a confirmed complete response in the first patient in the lowest-dose cohort our AAC trial and have therefore decided to continue the AAC trial. We remain focused on optimizing the potential of our eAPC and AAC platforms to meet the significant unmet medical needs of patients with HPV16+ tumors. We look forward to data from both these programs later in the year.”

2022 Full Year and Recent Portfolio Updates

Clinical Programs:

SQZ^® Enhanced Antigen Presenting Cell (“eAPC”) Platform in Oncology

Received FDA fast track designation for the treatment of HPV16+ tumors
Stable disease observed in two out of four evaluable patients in eAPC Phase 1/2 trial including a pronounced pharmacodynamic response in a patient with prolonged stable disease
Interim results from the ongoing SQZ^® eAPC Phase 1/2 trial showed favorable safety data and the investigational therapy was generally well tolerated
Strong enrollment rate on track to report clinical data for the highest-dose monotherapy cohort in the middle of 2023

SQZ^® Activating Antigen Carriers (“AAC”) Platform in Oncology

A confirmed complete response (CR), by RECIST 1.1 criteria, was observed in the first patient in the lowest-dose cohort of the SQZ-AAC-HPV-101 Phase 1 clinical trial for HPV16+ solid tumors
In light of the response, the company has decided to continue to enroll patients in the SQZ-AAC-HPV-101 clinical trial; Two additional patients have been dosed in the lowest-dose cohort and the dose-limiting toxicity (DLT) period has been completed
The recommendation of the Study Safety Committee is for the company to move directly to enrolling patients in the highest-dose cohort
Initial clinical data from the highest-dose cohort is anticipated in the fourth quarter of 2023
Published comprehensive preclinical research in Frontiers in Immunology

Earlier Stage Programs:

The company will continue to explore partnerships and collaborations for its earlier stage assets and programs, including SQZ^® Tolerizing Antigen Carriers (“TAC”) Platform in Immune Tolerance

2022 Full Year Financial Highlights

Revenue for the year ended December 31, 2022, was $21.5 million compared to $27.1 million for the year ended December 31, 2021
Research and development expenses for the year ended December 31, 2022, were $71.0 million compared to $70.1 million for the year ended December 31, 2021
General and administrative expenses for the year ended December 31, 2022, were $26.3 million compared to $25.7 million for the year ended December 31, 2021
Restructuring charges for the year ended December 31, 2022, were $4.9 million, primarily composed of $4.1 million in one-time termination benefits payable to employees included in the 60% workforce reduction, and $0.8 million in non-cash restructuring charges.
Net loss for the year ended December 31, 2022, was $79.5 million, compared to $68.7 million for the year ended December 31, 2021
As of December 31, 2022, the Company had cash and cash equivalents of $63.7 million and anticipates this will be sufficient to fund operating expenses and capital expenditure requirements into 2024

An updated investor presentation is available on the Events & Presentations page within the investor relations section of the company’s corporate website, investors.sqzbiotech.com. Based on guidance from the SEC, investors should note that the company may utilize its corporate website to post updated corporate and scientific presentations. It is possible that the information posted there could be deemed to be material information.

About SQZ Biotechnologies

SQZ Biotechnologies is a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies. The company’s proprietary Cell Squeeze^® technology offers the unique ability to deliver multiple biological materials into many patient cell types to engineer what the company believes can be a broad range of potential therapeutics. The company’s goal is to create well-tolerated cell therapies that can provide therapeutic benefit for patients and improve the patient experience over existing cell therapy approaches. With production timelines under 24 hours and the opportunity to eliminate preconditioning and lengthy hospital stays, the company believes its approach could change the way people think about cell therapies. For more information, please visit www.sqzbiotech.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements relating to the timing and outcome of the company’s clinical trials, clinical safety and efficacy of its therapeutic candidates and the potential addressable market for the company’s therapeutic candidates. These forward-looking statements are based on management’s current expectations. Actual results could differ from those projected in any forward-looking statements due to several risk factors. Such factors include, among others, risks and uncertainties related to the company’s significant losses incurred since inception and expectation to incur significant additional losses for the foreseeable future; the company’s need for additional funding; our ability to continue as a going concern; our ability to successfully execute and achieve the anticipated benefits of our restructuring plan; the development of the company’s initial product candidates, upon which its business is highly dependent; the impact of the COVID-19 pandemic on the company’s operations and clinical activities; the lengthy, expensive, and uncertain process of clinical drug development, including uncertain outcomes of clinical trials and potential delays in regulatory approval; and protection of the company’s proprietary technology, intellectual property portfolio and the confidentiality of its trade secrets. These and other important factors discussed under the caption “Risk Factors” in the company’s Quarterly Report on Form 10-Q, the company’s Annual Report on Form 10-K, and other filings with the U.S. Securities and Exchange Commission could cause actual results to differ materially from those indicated by the forward-looking statements. Any forward-looking statements represent management’s estimates as of this date and the company undertakes no duty to update these forward-looking statements, whether as a result of new information, the occurrence of current events, or otherwise, unless required by law.

SQZ BIOTECHNOLOGIES COMPANY Condensed Consolidated Statements of Operations (In thousands, except share and per share amounts) (unaudited)
	YEAR ENDED DECEMBER 31,
	2022			2021
Collaboration revenue	$	21,478		$	27,098
Operating expenses:
Research and development		70,984			70,148
General and administrative		26,319			25,719
Restructuring charges		4,859			—
Total operating expenses		102,162			95,867
Loss from operations		(80,684	)		(68,769	)
Other income, net		1,220			28
Net loss		(79,464	)		(68,741	)
Net loss per share attributable to common stockholders, basic and diluted	$	(2.76	)	$	(2.49	)
Weighted-average common shares outstanding, basic and diluted		28,812,904			27,578,844

SQZ BIOTECHNOLOGIES COMPANY Condensed Consolidated Balance Sheets (In thousands) (unaudited)
	YEAR ENDED DECEMBER 31,
	2022		2021
Assets
Cash and cash equivalents	$	63,709	$	143,513
Other current assets		4,495		7,122
Total current assets		68,204		150,635
Other assets		31,696		75,517
Total assets	$	99,900	$	226,152
Liabilities and Stockholders’ Equity
Current liabilities		21,843		33,224
Long term liabilities		20,909		68,952
Total liabilities		42,752		102,176
Total stockholders’ equity		57,148		123,976
Total liabilities and stockholders’ equity	$	99,900	$	226,152

View source version on businesswire.com: https://www.businesswire.com/news/home/20230322005188/en/

SQZ Biotechnologies Investor and Media Relations:

Mike Kaiser

[email protected]

857-760-0398

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Biotechnology Health Oncology Clinical Trials

MEDIA:

Logo

March 22, 2023 4:48 pm

ALERT: The M&A Class Action Firm Continues Investigating the Merger – ROCC, UNVR, CVT, DSEY

NEW YORK, March 22, 2023 (GLOBE NEWSWIRE) — Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating:

Ranger Oil Corp. (NASDAQ:

ROCC

), relating to its proposed sale to Baytex Energy Corp. Under the terms of the agreement, ROCC shareholders are expected to receive 7.49 shares of Baytex and $13.31 in cash per share they own. Click here for more information: https://www.monteverdelaw.com/case/ranger-oil-corp. It is free and there is no cost or obligation to you.
Univar Solutions Inc. (NYSE:

UNVR

), relating to its sale to affiliates of Apollo Global Management, Inc. Under the terms of the agreement, UNVR shareholders will receive $36.15 in cash per share they own. Click here for more information: https://www.monteverdelaw.com/case/univar-solutions-inc. It is free and there is no cost or obligation to you.
Cvent Holding Corp. (NASDAQ:

CVT

), relating to its sale to equity funds managed by Blackstone Inc. Click here for more information: https://www.monteverdelaw.com/case/cvent-holding-corp. It is free and there is no cost or obligation to you.
Diversey Holdings, Ltd. (NASDAQ:

DSEY

), relating to its proposed sale to Solenis. Under the terms of the agreement DSEY shareholders are expected to receive $8.40 in cash per share they own. Click here for more information: https://www.monteverdelaw.com/case/diversey-holdings-ltd. It is free and there is no cost or obligation to you.

About Monteverde & Associates PC

We are a national class action securities and consumer litigation law firm that has recovered millions of dollars for shareholders and iscommitted to protecting investors and consumers from corporate wrongdoing. Monteverde & Associates lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions, whereby they protect investors by recovering money and remedying corporate misconduct. Mr. Monteverde, who leads the firm, has been recognized by Super Lawyers as a Rising Star in Securities Litigation in 2013 and 2017-2019, an award given to less than 2.5% of attorneys in a particular field. He has also been selected by Martindale-Hubbell as a 2017-2020 Top Rated Lawyer. Our firm’s recent successes include changing the law in a significant victory that lowered the standard of liability under Section 14(e) of the Exchange Act in the Ninth Circuit. Thereafter, our firm successfully preserved this victory by obtaining dismissal of a writ of certiorari as improvidently granted at the United States Supreme Court. Emulex Corp. v. Varjabedian, 139 S. Ct. 1407 (2019). Also, over the years the firm has recovered or secured over a dozen cash common funds for shareholders in mergers & acquisitions class action cases.

If you own common stock in any of the above listed companies and wish to obtain additional information and protect your investments free of charge, please visit our website or contact Juan E. Monteverde, Esq. either via e-mail at [email protected] or by telephone at (212) 971-1341.

Contact:
Juan E. Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4405
New York, NY 10118
United States of America
[email protected]
Tel: (212) 971-1341

Attorney Advertising. (C) 2023 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.

March 22, 2023 4:47 pm

Phillips Edison & Company, Inc. Invites You to Join Its First Quarter 2023 Earnings Conference Call

CINCINNATI, March 22, 2023 (GLOBE NEWSWIRE) — Phillips Edison & Company, Inc. (Nasdaq: PECO) (“PECO”), one of the nation’s largest owners and operators of grocery-anchored neighborhood shopping centers, will announce its first quarter earnings results on Tuesday, May 2, 2023, after the market close. PECO’s earnings release and supplemental information package will be posted on the Investor Relations section of the Company’s website at investors.phillipsedison.com. Chairman and Chief Executive Officer Jeff Edison, President Devin Murphy, and Chief Financial Officer John Caulfield will host an earnings conference call to discuss results, which will be webcast on Wednesday, May 3, 2023, at 12:00 p.m. ET.

First Quarter 2023 Earnings Conference Call Details:

Date: Wednesday, May 3, 2023

Time: 12:00 p.m. ET

Toll-Free Dial-In Number: (888) 210-4659

International Dial-In Number: (646) 960-0383

Conference ID: 2035308

Webcast:
First Quarter 2023 Webcast Link

Webcasts are archived on PECO’s Investor Relations website.

Connect with PECO:

For additional information, please visit https://www.phillipsedison.com/
Follow PECO on:
Twitter at https://twitter.com/PhillipsEdison
Facebook at https://www.facebook.com/phillipsedison.co
Instagram at https://www.instagram.com/phillips.edison/; and
Find PECO on LinkedIn at https://www.linkedin.com/company/phillipsedison&company

About Phillips Edison & Company

Phillips Edison & Company, Inc. (“PECO”) is one of the nation’s largest owners and operators of omni-channel grocery-anchored shopping centers. Founded in 1991, PECO has generated strong results through its vertically integrated operating platform and national footprint of well-occupied shopping centers. PECO’s centers feature a mix of national and regional retailers providing necessity-based goods and services in fundamentally strong markets throughout the United States. PECO’s top grocery anchors include Kroger, Publix, Albertsons and Ahold Delhaize. As of December 31, 2022, PECO managed 291 shopping centers, including 271 wholly-owned centers comprising 31.1 million square feet across 31 states, and 20 shopping centers owned in one institutional joint venture. PECO is exclusively focused on creating great omni-channel, grocery-anchored shopping experiences and improving communities, one neighborhood shopping center at a time.

PECO uses, and intends to continue to use, its Investor Relations website, which can be found at https://investors.phillipsedison.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.

Investors:

Kimberly Green, Vice President of Investor Relations
(513) 692-3399
[email protected]

Stephanie Hout, Director of Investor Relations
(513) 746-2594
[email protected]

March 22, 2023 4:47 pm

Cyclerion Reports Corporate Update and Full Year 2022 Financial Results

CAMBRIDGE, Mass., March 22, 2023 (GLOBE NEWSWIRE) — Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced corporate updates including advances in its zagociguat (formerly CY6463) mitochondrial disease program.

The Company previously reported clinical data in adult patients with MELAS* that indicate that zagociguat may have potential as a first-ever therapy for patients with this rare, genetic mitochondrial disease. In Q4 2022, Cyclerion met with the United States Food and Drug Administration (FDA) and incorporated feedback from regulatory and mitochondrial disease clinical experts to refine the design of a Phase 2b study to evaluate zagociguat in patients with MELAS. More recently, Cyclerion filed a request with the FDA for Orphan Drug Designation and manufactured drug product to support the Phase 2b study.

Given the significant capital and capabilities necessary to ensure that the Phase 2b study is executed efficiently and with the highest quality, and the currently unfavorable capital market conditions, the Company is actively evaluating the best combination of capital, capabilities, and transactions available to it to advance the development of zagociguat and its other clinical development candidates and to maximize shareholder value.

Cyclerion is working expeditiously to deliver this potential treatment to help address the immense unmet needs of patients with MELAS, a patient population in desperate need of therapies. The Company is also working to develop and execute on the optimal strategy to advance its other wholly-owned assets: CY3018, a next-generation CNS-penetrant sGC stimulator that preferentially targets the brain and has demonstrated a unique pharmacological signature and promising profile for neuropsychiatric diseases, and olinciguat, a vascular-targeted sGC stimulator which has attractive profile in cardiovascular and cardiopulmonary diseases, areas where sGC stimulators have previously demonstrated clinical benefit.

Financial Position

Cash, cash equivalents, and restricted cash balance on December 31, 2022 was approximately $13.4 million, as compared to approximately $20.4 million on September 30, 2022.
Research and development expenses were approximately $31.5 million for the full year 2022, as compared to approximately $37.6 million for the full year 2021. The decrease of approximately $6.1 million was driven by decreases of approximately $1.0 million in non-cash stock-based compensation, approximately $0.3 million in salaries and other employee-related expenses, and approximately $6.8 million of facilities and operating costs, partially offset by increases of approximately $2.0 million related to zagociguat and CY3018 external research and development costs.
General and administrative expenses were approximately $14.5 million for the full year 2022, as compared to approximately $20.6 million for the full year 2021. The decrease of approximately $6.1 million was driven by decreases of approximately $2.3 million in non-cash stock-based compensation, approximately $1.0 million in salaries and other employee-related expenses, approximately $2.1 million in facilities and operating costs, and approximately $0.7 million in outside professional and corporate expenses.
Net Loss: Net loss was approximately $44.1 million for the full year 2022, as compared to $51.6 million for the full year 2021.

About Cyclerion Therapeutics

Cyclerion Therapeutics is a biopharmaceutical company on a mission to develop treatments for serious diseases. Cyclerion’s portfolio includes novel sGC stimulators that modulate a key node in a fundamental signaling network in both the CNS and the periphery. The multidimensional pharmacology elicited by the stimulation of sGC has the potential to impact a broad range of diseases. Zagociguat is a CNS-penetrant sGC stimulator that has shown rapid improvements across a range of endpoints reflecting multiple domains of disease activity, including mitochondrial disease-associated biomarkers. CY3018 is a CNS-targeted sGC stimulator in preclinical development that preferentially localizes to the brain and has a pharmacology profile that suggests its potential for the treatment of neuropsychiatric diseases and disorders. Praliciguat is a systemic sGC stimulator that is licensed to Akebia and being advanced in rare kidney disease. Olinciguat is a vascular sGC stimulator that the Company intends to out-license for cardiovascular diseases. For more information about Cyclerion, please visit https://www.cyclerion.com/ and follow us on Twitter (@Cyclerion) and LinkedIn (www.linkedin.com/company/cyclerion).

Forward Looking Statement

Certain matters discussed in this press release are “forward-looking statements”. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should”, “positive” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding the assessment of the best combination of capital, capabilities, and transactions available to it, the success of any such potential transactions in delivering any future value to the Company, the sufficiency of any expected revenues to provide liquidity and capital resources to pursue any of our go-forward business plans regarding any product candidate, the potential for zagociguat in the treatment of MELAS, the potential for CY3018 in the treatment of CNS diseases, the potential for olinciguat in the treatment of cardiovascular and cardiopulmonary diseases, the potential for any successful development of any of our assets, and other trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the success of any transactions in delivering any future value to the company, our ability to succeed with any go-forward business, the sufficiency of any expected proceeds to provide liquidity and capital resources to pursue any of our go-forward business plans regarding any product candidate (including without limitation our ability to fund additional clinical trials); any ability to successfully demonstrate the efficacy, safety and therapeutic effectiveness of any product candidate; any results of clinical studies not necessarily being indicative of or supported by the final results of subsequent clinical trials; the timing of and ability to pursue, obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, product candidates; the Company’s ability to successfully defend its intellectual property or obtain necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the product candidates, if approved; and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance.

* MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes syndrome)

Investors and Media Inquiries

Cyclerion Investor Relations
Phone: 857-327-8778
Email: [email protected]

March 22, 2023 4:47 pm

Cumulus Media’s Westwood One Presents Exclusive Multi-Platform Audio Coverage of the 2023 NCAA® Division I Men’s Basketball Sweet Sixteen® and Elite Eight®

NEW YORK, March 22, 2023 (GLOBE NEWSWIRE) — Cumulus Media’s Westwood One (NASDAQ: CMLS), the largest audio network in the U.S. and the official network radio partner of the NCAA, will broadcast live coverage of the Men’s Sweet Sixteen on Thursday, March 23 and Friday, March 24 beginning at 6 p.m. ET each night.

Westwood One will also broadcast live coverage of the Men’s Elite Eight on Saturday, March 25 and Sunday, March 26 as well as the NCAA Men’s Final Four® on Saturday, April 1 and the national championship game on Monday, April 3 in both English and Spanish.

Westwood One’s schedule for the 2023 NCAA Men’s Basketball Sweet Sixteen and Elite Eight:

Sweet Sixteen Doubleheaders:

Thursday, March 23 at 6:00 p.m. ET
- (7) Michigan State vs. (3) Kansas State
- (8) Arkansas vs. (4) UConn
- (9) FAU vs. (4) Tennessee
- (3) Gonzaga vs. (2) UCLA
Friday, March 24 at 6:00 p.m. ET
- 5) San Diego State vs. (1) Alabama
- (5) Miami (FL) vs. (1) Houston
- (15) Princeton vs. (6) Creighton
- (3) Xavier vs. (2) Texas

Elite Eight Doubleheaders:

Saturday, March 25, 5:30 p.m. ET
Sunday, March 26, 1:30 p.m. ET

Where to Listen
Westwood One’s NCAA men’s tournament coverage can be heard on terrestrial radio stations nationwide and via SiriusXM, streamed online for free at NCAA.com/MarchMadness and on westwoodonesports.com. Additionally, the broadcasts will be available for free via the NCAA March Madness Live app or The Varsity Network app. Fans can also access live audio via Alexa-enabled devices by asking to “Open Westwood One Sports”. TuneIn premium subscribers can also hear all the action live.

Westwood One will produce an outstanding lineup of college basketball programming including Great Moments in Tournament History, a 60-second daily historical feature, plus one-hour preview shows The NCAA Tournament Today, The Final Four Show, and Championship Monday.

For a complete schedule of games, announcer bios, exclusive audio content, and a list of radio stations airing Westwood One’s broadcast of the NCAA Men’s Division I Basketball Championship, log on to westwoodonesports.com.

NCAA, First Four, Final Four, Sweet Sixteen, Elite Eight, and March Madness are trademarks of the National Collegiate Athletic Association.

About Westwood One Sports
Westwood One Sports is home to some of the most exciting sports broadcasts on radio. In addition to NCAA Basketball, including the NCAA Men’s and Women’s Championships and the Final Four; it is also the exclusive provider of the Men’s and Women’s Frozen Four, the Men’s and Women’s Lacrosse Championship, and the Men’s and Women’s College World Series. Westwood One has been the exclusive network radio partner to the NFL since 1987. Westwood One also distributes and represents CBS Sports Radio. On social media, join the Westwood One Sports community on Twitter at twitter.com/westwood1sports. For more information, visit www.westwoodonesports.com.

About Cumulus Media
Cumulus Media (NASDAQ: CMLS) is an audio-first media company delivering premium content to over a quarter billion people every month — wherever and whenever they want it. Cumulus Media engages listeners with high-quality local programming through 404 owned-and-operated radio stations across 85 markets; delivers nationally-syndicated sports, news, talk, and entertainment programming from iconic brands including the NFL, the NCAA, the Masters, CNN, the AP, the Academy of Country Music Awards, and many other world-class partners across more than 9,400 affiliated stations through Westwood One, the largest audio network in America; and inspires listeners through the Cumulus Podcast Network, its rapidly growing network of original podcasts that are smart, entertaining and thought-provoking. Cumulus Media provides advertisers with personal connections, local impact and national reach through broadcast and on-demand digital, mobile, social, and voice-activated platforms, as well as integrated digital marketing services, powerful influencers, full-service audio solutions, industry-leading research and insights, and live event experiences. Cumulus Media is the only audio media company to provide marketers with local and national advertising performance guarantees. For more information visit www.cumulusmedia.com.

About the NCAA

The NCAA is a diverse association of more than 1,100 member colleges and universities that prioritize academics, well-being and fairness to create greater opportunities for nearly half a million student-athletes each year. The NCAA provides a pathway to higher education and beyond for student-athletes pursuing academic goals and competing in NCAA sports. More than 54,000 student-athletes experience the pinnacle of intercollegiate athletics by competing in NCAA championships each year. Visit ncaa.org and ncaa.com for more details about the Association and the corporate partnerships that support the NCAA and its student-athletes. The NCAA is proud to have AT&T, Capital One and Coca-Cola as official corporate champions and the following elite companies as official corporate partners: Aflac, Buffalo Wild Wings, Buick, Dick’s Sporting Goods, Great Clips, Invesco, LG, Marriott Bonvoy, Nabisco, Nissan, Pizza Hut, Reese’s, TurboTax, Unilever and Wendy’s.

Contact: Karen Glover | Westwood One | [email protected]

March 22, 2023 4:46 pm

Kadant Named to Newsweek’s List of America’s Greatest Workplaces for Diversity 2023

WESTFORD, Mass., March 22, 2023 (GLOBE NEWSWIRE) — Kadant Inc. (NYSE: KAI) announced it was recognized as one of “America’s Greatest Workplaces for Diversity 2023” by Newsweek magazine. The recognition was awarded to 1,000 companies across 34 industries.

“We are honored to be recognized for our efforts around building a diverse and welcoming workplace for our employees,” said Jeffrey L. Powell, president and chief executive officer of Kadant. “Our people-centric work environment is designed to create opportunity for all employees to grow into highly effective contributors focused on delivering value and exceptional customer experiences.”

The companies included in America’s Greatest Workplaces for Diversity 2023 were selected based on an independent review of publicly available data, interviews with HR professionals, and an anonymous online survey of employees at companies with 1,000 or more employees in the U.S. Respondents were asked questions about corporate culture, working environment, and other subjects at both their own companies and others they were familiar with. More information about the 2023 rankings is available at www.newsweek.com/rankings/americas-greatest-workplaces-2023-diversity. All registered trademarks are property of their respective owners.

About Kadant

Kadant is a global supplier of technologies and engineered systems that drive Sustainable Industrial Processing. The Company’s products and services play an integral role in enhancing efficiency, optimizing energy utilization, and maximizing productivity in process industries. Kadant is based in Westford, Massachusetts, with approximately 3,100 employees in 20 countries worldwide. For more information, visit www.kadant.com.

Safe Harbor Statement

The following constitutes a “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that involve a number of risks and uncertainties, including forward-looking statements about our products, technologies, and markets. These forward-looking statements represent our expectations as of the date of this press release. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause our actual results to differ materially from these forward-looking statements as a result of various important factors, including those set forth under the heading “Risk Factors” in Kadant’s annual report on Form 10-K for the fiscal year ended December 31, 2022 and subsequent filings with the Securities and Exchange Commission.

Contacts

Investor Contact Information:
Michael McKenney, 978-776-2000
[email protected]
or
Media Contact Information:
Wes Martz, 269-278-1715
[email protected]

March 22, 2023 4:46 pm

Cumulus Media’s Westwood One Presents Exclusive Live Audio Coverage of the 2023 NCAA® Division I Women’s Basketball Championship

Broadcasts Include Women’s Sweet Sixteen® through the National Championship

NEW YORK, March 22, 2023 (GLOBE NEWSWIRE) — Cumulus Media’s Westwood One (NASDAQ: CMLS), the largest audio network in the U.S. and the official network audio broadcast partner of the NCAA, will present exclusive live coverage of the NCAA Division I Women’s Basketball Championship beginning on Friday, March 24 and Saturday, March 25 with the Sweet Sixteen®. Coverage will continue on Sunday and Monday with the Elite Eight® and culminate with the Women’s Final Four® on Friday, March 31, and the women’s national championship game on Sunday, April 2, from Dallas.

Westwood One’s broadcast crew for the Women’s Final Four and National Championship will consist of Ryan Radtke as play-by-play announcer, Debbie Antonelli as lead analyst, and Krista Blunk as courtside reporter. This will be Antonelli’s 20th season as lead analyst and 27th season overall with the network. Blunk has been an analyst for the network since 2005 and has served as courtside reporter for the Women’s Final Four every season since 2012.

Fans can access all the action on AM/FM radio, on SiriusXM, and on westwoodonesports.com. Additionally, the broadcasts will be available for free via the NCAA March Madness Women’s Basketball app or The Varsity Network app. Fans can also access live audio via Alexa-enabled devices by asking to “Open Westwood One Sports”. TuneIn premium subscribers can also hear all the action live.

Westwood One’s Complete 2023 NCAA Women’s Tournament Coverage Schedule:

Sweet 16 Doubleheaders:
- Friday, March 24
  - 2:15 p.m. ET – Greenville, SC
    - (9) Miami (FL) vs. (4) Villanova
    - (3) LSU vs. (2) Utah
  - 7:15 p.m. ET – Seattle, WA
    - (6) Colorado vs. (2) Iowa
    - (8) Ole Miss vs. (5) Louisville
- Saturday, March 25th
  - 11:15 a.m. ET – Greenville, SC
    - (3) Notre Dame vs. (2) Maryland
    - (4) UCLA vs. (1) South Carolina
  - 3:45 p.m. ET – Seattle, WA
    - (3) Ohio State vs. (2) UConn
    - (4) Tennessee vs. (1) Virginia Tech
Elite 8 Doubleheader:
- Sunday, March 26^th
  - 6:45 p.m. ET
    - Miami (FL)/Villanova winner vs. LSU/Utah winner
    - Colorado/Iowa winner vs. Ole Miss/Louisville winner
- Monday, March 27^th
  - 6:45 p.m. ET
    - Notre Dame/Maryland winner vs. UCLA/South Carolina winner
    - Ohio State/UConn winner vs. Tennessee/Virginia Tech winner
Final Four:
- Friday, March 31^stat 6:30 p.m. ET
National Championship Game:
- Sunday, April 2^ndat 3:00 p.m. ET

For a complete schedule of games, announcer bios, exclusive audio content, and a list of radio stations airing Westwood One’s broadcast of the NCAA Women’s Division I Basketball Championship, log on to westwoodonesports.com.

Westwood One is the exclusive broadcast radio, digital audio, distribution, and licensing partner for the NCAA Championships.

Westwood One has broadcast the NCAA Women’s Final Four and Championship for more than 25 years. In addition, the network has broadcast the NCAA Men’s Basketball Tournament since 1982 and every game of March Madness® on multiple platforms since 2005.

NCAA, First Four, Sweet Sixteen, Elite Eight, Final Four, and March Madness are registered trademarks of the National Collegiate Athletic Association.

About Westwood One Sports

Westwood One Sports is home to some of the most exciting sports broadcasts on radio. In addition to NCAA Basketball, including the NCAA Men’s and Women’s Championships and the Final Four; it is also the exclusive provider of the Men’s and Women’s Frozen Four, the Men’s and Women’s Lacrosse Championship, and the Men’s and Women’s College World Series. Westwood One has been the exclusive network radio partner to the NFL since 1987. Westwood One also distributes and represents CBS Sports Radio. On social media, join the Westwood One Sports community on Twitter at twitter.com/westwood1sports. For more information, visit www.westwoodonesports.com.

About Cumulus Media

Cumulus Media (NASDAQ: CMLS) is an audio-first media company delivering premium content to over a quarter billion people every month — wherever and whenever they want it. Cumulus Media engages listeners with high-quality local programming through 404 owned-and-operated radio stations across 85 markets; delivers nationally-syndicated sports, news, talk, and entertainment programming from iconic brands including the NFL, the NCAA, the Masters, CNN, the AP, the Academy of Country Music Awards, and many other world-class partners across more than 9,400 affiliated stations through Westwood One, the largest audio network in America; and inspires listeners through the Cumulus Podcast Network, its rapidly growing network of original podcasts that are smart, entertaining and thought-provoking. Cumulus Media provides advertisers with personal connections, local impact and national reach through broadcast and on-demand digital, mobile, social, and voice-activated platforms, as well as integrated digital marketing services, powerful influencers, full-service audio solutions, industry-leading research and insights, and live event experiences. Cumulus Media is the only audio media company to provide marketers with local and national advertising performance guarantees. For more information visit www.cumulusmedia.com.

Contact: Karen Glover | Westwood One | [email protected]